Excerpt from Central Sterile Corneal UlcerationSynonyms, Key Words, and Related Terms: central sterile corneal ulceration, neurotrophic ulcer, corneal ulcer, corneal stroma, corneal lesion, keratitis, corneal inflammation, stromal ulceration Please click here to view the full topic text: Central Sterile Corneal UlcerationBackgroundA corneal ulcer is defined as a disruption of the epithelial layer with involvement of the corneal stroma. This condition is associated with inflammation, either sterile or infectious. The primary purpose of this article is to highlight the pathogenesis of noninfectious stromal ulceration. The infective causes and mechanisms of autoimmune ulcerative keratitis, particularly peripheral, are not included within this article. PathophysiologyAn understanding of the pathophysiology of sterile corneal ulceration requires a review of the processes involved in epithelial and stromal wound healing, as well as an examination of the role of precorneal tear film, corneal nerves, proteolytic enzymes, and cytokines. Epithelial wound healing After 24-30 hours, mitosis begins to restore epithelial cell population. Basal and limbal stem cells contribute to mitosis. A sufficient supply of progenitor stem cells to facilitate epithelial cell proliferation is important for the cornea. A deficiency of limbal stem cells, from either disease (eg, aniridia) or trauma (eg, chemical burn), can preclude adequate epithelial wound healing. Stromal wound healing Stromal wound healing occurs via stromal keratocyte migration, proliferation, and deposition of extracellular matrix molecules, including collagen (specifically type III), adhesion proteins (eg, fibronectin, laminin), and glycosaminoglycans. These processes are facilitated by a phenotypic change among quiescent keratocytes to become active myofibroblasts, a task mediated by transforming growth factor-beta (of presumptive epithelial origin). Stromal necrosis and degradation The role of the precorneal tear film in ulceration The exposure of the bare corneal stroma to its environment secondary to deficient or impaired epithelial wound healing is thought to contribute to stromal degradation through environmental factors, cytokines, lytic enzymes, and neutrophils in the tear film. Direct neutrophil adhesion to the corneal stroma theoretically allows hydrolytic and collagenolytic enzymes, including MMP-8 (neutrophil collagenase), to contribute to the degradation of the corneal stromal extracellular matrix. Dohlman et al (1969) and subsequently Kenyon et al (1979) demonstrated that a glued on methylacrylate lens applied to a rabbit alkali burn model of corneal ulceration protected the stroma from collagenolysis by neutrophils and injured epithelial cells.8, 9 Keratocyte fibroblasts also may contribute to this milieu. The prevention of neutrophil infiltration and the promotion of epithelialization are thought to be at least some of the mechanisms responsible for the beneficial effect of amniotic membrane graft use in preventing stromal ulceration. In addition, cytokines, such as hepatocyte growth factor (HGF), keratocyte growth factor (KGF), and EGF, are produced by the lacrimal gland and, thus, are present in tears. HGF is up-regulated in response to corneal injury in parallel with increased aqueous tear production. In the wounded cornea, these cytokines may play an important role in regulating epithelial healing. Inflammatory cytokines, including IL-1alpha, are detectable in normal human tears and may be important in causing further degradation of the corneal stroma, either directly by inducing keratocyte apoptosis or by recruiting inflammatory cells via their chemotactic properties. In addition, an irregular tear film and a decreased tear film breakup time over the area of the bare stroma can cause a delle effect that may contribute to an unfavorable cellular environment for the viability and proliferation of stromal keratocytes. The role of cytokines Not to be eclipsed by stromal influences, epithelial cells modulate important keratocyte responses to epithelial cell injury. Keratocyte wound healing processes, including MMP production and regulation, HGF and KGF production, and keratocyte apoptosis, are mediated via various cytokines, including stimulators like IL-1 and soluble Fas ligand and major inhibitor TGF-beta2. Anterior stromal keratocyte cell death is an important feature of corneal wounding and stromal degradation. Beyond keratocyte cell death caused by mechanical injury or necrosis associated with neutrophil infiltration, IL-1– and Fas ligand–mediated apoptosis is an important stromal response to epithelial injury. Since both of these cytokines can be produced by keratocytes, autocrine modulation of these responses may occur. IL-1 and PDGF also regulate MMP expression in stromal keratocytes. The exact keratocyte response to IL-1 is likely to be determined by the cytokine milieu in which the targeted keratocyte resides. Other cytokine systems that have demonstrated fibroblast apoptosis include TNF and bone morphogenic protein (BMP).Studies have shown that autologous serum and umbilical cord serum harbor many growth factors and neuropeptides like EGF, TGF-beta, vitamin A, fibronectin, substance P, IGF-1, NGF, and other cytokines that are essential for the proliferation, differentiation, and maturation of the ocular surface epithelium. Treatment with autologous serum and umbilical cord serum eye drops seem promising for the restoration of the ocular surface epithelial integrity in patients with neurotrophic keratitis and severe dry eye syndrome.10 Platelets are known for their ability to heal epithelial and internal wounds. They have storage pools of growth factors, including platelet-derived growth factors, TGF-beta, epithelial growth factors, fibroblast growth factors, insulinlike growth factor I, and vascular endothelial growth factors. Autologous platelet-rich plasma has a large quantity of growth factors that have been found to promote the healing of dormant corneal ulcers and to reduce pain and inflammation.11 Platelet-activating factor (PAF) is a potent bioactive lipid that is generated in the cornea after injury. Corneal cells synthesize PAF as early as 30 minutes after injury and increased accumulation is observed at later times, which is, in part, due to the presence of inflammatory cells that arrive at the cornea and actively produce PAF. PAF is a strong inflammatory mediator and inducer of the expression of specific genes, such as some metalloproteinases, urokinase plasminogen activators, and TIMPs. It delays corneal epithelial wound healing by inhibiting adhesion of epithelial cells to the basement membrane and by increasing apoptosis of stromal cells. All these activities exerted by PAF are receptor mediated. Corneal epithelial cells, keratocytes, and endothelial cells express the PAF receptor, and, in corneal epithelial cells, injury up-regulates PAF receptor gene expression. The role of PAF receptor antagonists in preventing corneal injury is under investigation. Plasminogen is synthesized in the cornea and can be activated to plasmin by a plasminogen activator. This synthesis is stimulated by IL-1alpha and IL-1beta. In turn, plasmin is able to activate latent collagenase. This system could lead to the collagen degradation of corneal ulceration. Studies have demonstrated that uPA (urokinase plasminogen activator), but not tPA (tissue plasminogen activator), is induced in the migrating epithelial cells during corneal epithelial wound healing. Amiloride, a specific uPA inhibitor, effectively decreases uPA activity in the cornea as well as in the tear fluid and favorably affects corneal healing. A majority of inflammatory cytokines use the nuclear factor (NF)-κB pathway for signaling. Saika et al 2005 studied a mouse corneal alkali burn model to evaluate the therapeutic potential of topical administration of SN50, a cell-permeable peptide inhibitor of NF-κB.12 They showed that topical administration of SN50 prevents epithelial defects and corneal ulceration after a central alkali burn.12Thymosin beta-4 is a water-soluble polypeptide that promotes corneal wound healing and decreases inflammation.13 Thymosin beta-4 interferes with NF-κB signaling pathways and suppresses NF-κB phosphorylation, activity, and nuclear translocation in cultured human corneal epithelial cells. Thymosin beta-4 can potentially be used as a potent anti-inflammatory therapy in inflammatory corneal conditions.13 Saika et al (2007) concluded that overexpression of peroxisome proliferator-activated receptor-gamma (PPARgamma) may represent an effective new strategy for the treatment of ocular surface burns.14 Adenoviral gene introduction of PPARgamma inhibited activation of ocular fibroblasts and macrophages in vitro and also induced anti-inflammatory and antifibrogenic responses in an alkali-burned mouse cornea. Cytokines and trophic factors from the corneal nerves, tear film, conjunctiva, conjunctival vessels, endothelium, and anterior chamber may have important modulating effects on corneal epithelial and stromal healing responses and, thus, corneal ulceration. FrequencyUnited StatesThe incidence rate depends on the etiology of the corneal ulcer. Mortality/MorbidityCorneal scarring, decreased vision, neovascularization, perforation, and blindness are associated with this condition. SexBecause of an increased incidence of injuries, this condition may be seen more frequently in males than females. Please click here to view the full topic text: Central Sterile Corneal Ulceration |
| About Us | Privacy | Code of Ethics | Terms of Use | Contact Us | Advertising | Institutional Subscribers |
|
|
|||
|
| Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. The authors, editors, and publisher of this journal have used their best efforts to provide information that is up-to-date and accurate and is generally accepted within medical standards at the time of publication. However, as medical science is constantly changing and human error is always possible, the authors, editors, and publisher or any other party involved with the publication of this article do not warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should confirm the information in this article from other sources prior to use. In particular, all drug doses, indications, and contraindications should be confirmed in the package insert. FULL DISCLAIMER |